PT  - JOURNAL ARTICLE
AU  - Aleta, Alberto
AU  - Martín-Corral, David
AU  - Bakker, Michiel A.
AU  - y Piontti, Ana Pastore
AU  - Ajelli, Marco
AU  - Litvinova, Maria
AU  - Chinazzi, Matteo
AU  - Dean, Natalie E.
AU  - Halloran, M. Elizabeth
AU  - Longini, Ira M.
AU  - Pentland, Alex
AU  - Vespignani, Alessandro
AU  - Moreno, Yamir
AU  - Moro, Esteban
TI  - Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas
AID  - 10.1101/2020.12.15.20248273
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.15.20248273
4099  - http://medrxiv.org/content/early/2021/12/26/2020.12.15.20248273.short
4100  - http://medrxiv.org/content/early/2021/12/26/2020.12.15.20248273.full
AB  - Detailed characterization of SARS-CoV-2 transmission across different settings can help design less disruptive interventions. We used real-time, privacy-enhanced mobility data in the New York City and Seattle metropolitan areas to build a detailed agent-based model of SARS-CoV-2 infection to estimate the where, when, and magnitude of transmission events during the pandemic’s first wave. We estimate that only 18% of individuals produce most infections (80%), with about 10% of events that can be considered super-spreading events (SSEs). Although mass-gatherings present an important risk for SSEs, we estimate that the bulk of transmission occurred in smaller events in settings like workplaces, grocery stores, or food venues. The places most important for transmission change during the pandemic and are different across cities, signaling the large underlying behavioral component underneath them. Our modeling complements case studies and epidemiological data and indicates that real-time tracking of transmission events could help evaluate and define targeted mitigation policies.Competing Interest StatementM.E.H. reports grants from the National Institute of General Medical Sciences during the conduct of the study; M.A. received research funding from Seqirus; A.V. reports grants and personal fees from Metabiota, Inc., outside of the submitted work; M.C. and A.PyP report grants from Metabiota, Inc., outside of the submitted work. The authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementN.E.D., I.M.L., MEH, A.PyP. and A.V. acknowledge the support of NIH/NIAID R56-AI148284. M.C. and A.V. acknowledge support from Google Cloud Healthcare and Life Sciences Solutions via the GCP research credits program. E.M. acknowledges partial support by MINECO (FIS2016-78904-C3-3-P and PID2019-106811GB-C32). Y.M. acknowledges partial support from the Government of Aragon and FEDER funds, Spain through grant E36-20R (FENOL), and by MINECO and FEDER funds (FIS2017-87519-P). A.A. and Y.M. acknowledge support from Banco Santander (Santander-UZ 2020/0274) and Intesa Sanpaolo Innovation Center. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MIT Committee on the Use of Humans as Experimental Subjects. COUHES Exemption number #1812635935I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from Cuebiq through their Data for Good program, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Aggregated data used in the models are however available from the authors upon reasonable request and permission of Cuebiq. Other data used comes from the American Community Survey (5-year) from the Census, which is publicly available.